Uni-Bio Science Group Ltd
HKEX:690
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Uni-Bio Science Group Ltd
Free Cash Flow
Uni-Bio Science Group Ltd
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Uni-Bio Science Group Ltd
HKEX:690
|
Free Cash Flow
HK$70.9m
|
CAGR 3-Years
52%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hbm Holdings Ltd
HKEX:2142
|
Free Cash Flow
$49.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
China Regenerative Medicine International Ltd
HKEX:8158
|
Free Cash Flow
HK$3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CK Life Sciences Intl (Holdings) Inc
HKEX:775
|
Free Cash Flow
HK$202.1m
|
CAGR 3-Years
11%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
S
|
SinoMab BioScience Ltd
HKEX:3681
|
Free Cash Flow
-¥113.5m
|
CAGR 3-Years
35%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Essex Bio-Technology Ltd
HKEX:1061
|
Free Cash Flow
HK$131.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Uni-Bio Science Group Ltd
Glance View
Uni-Bio Science Group Ltd. is an investment holding company with interests in pharmaceutical research and development. The company employs 326 full-time employees The company went IPO on 2001-11-12. The firm operates through four segments. In-house Chemical Pharmaceutical Products segment is engaged in the manufacture and sales of in-house chemical pharmaceutical products. Its chemical pharmaceutical products include Pinapu, among others. In-house Biological Pharmaceutical Products segment is engaged in the manufacture and sales of in-house biological pharmaceutical products. Its biological pharmaceutical products include GeneTime and GeneSoft, among others. In-house Biological Pipeline segment is engaged in the industrialization of in-house biological pipeline. Its biological pipeline products include Uni-E4 and Uni-PTH, among others. Third-party Pharmaceutical Products segment is engaged in the sales of third-party pharmaceutical products.
See Also
What is Uni-Bio Science Group Ltd's Free Cash Flow?
Free Cash Flow
70.9m
HKD
Based on the financial report for Dec 31, 2025, Uni-Bio Science Group Ltd's Free Cash Flow amounts to 70.9m HKD.
What is Uni-Bio Science Group Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 3Y
52%
Over the last year, the Free Cash Flow growth was 147%. The average annual Free Cash Flow growth rates for Uni-Bio Science Group Ltd have been 52% over the past three years .
